Skip to main content

Heron Therapeutics, Inc DEFA14A, filed Nov 9, 2026

Heron Therapeutics, Inc. (HRTX)

CorMedix agreed to acquire substantially all Heron Therapeutics assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, in a cash and stock transaction. Closing is expected in the first quarter of 2027, subject to stockholder approval, regulatory clearance and other customary conditions. AI summary

DEFA14A 2026-11-09
View Original
Added on November 09, 2026